BCM
ABCL icon

Bayesian Capital Management’s AbCellera Biologics ABCL Stock Holding History

Bayesian Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,090
Closed -$233K – 664
2023
Q2 		$233K Buy
36,090
+17,200
+91% +$117K 0.03% 601
2023
Q1 		$142K Sell
18,890
-16,500
-47% -$150K 0.02% 648
2022
Q4 		$359K Buy
35,390
+500
+1% +$5.78K 0.05% 438
2022
Q3 		$345K Buy
34,890
+8,100
+30% +$88.9K 0.07% 371
2022
Q2 		$285K Sell
26,790
-910
-3% -$7.71K 0.05% 499
2022
Q1 		$270K Buy
+27,700
New +$262K 0.04% 553
2021
Q3 		– Sell
-22,900
Closed -$504K – 364
2021
Q2 		$504K Buy
+22,900
New +$631K 0.13% 189

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return